Health
Therapy
Asia (Non-China)

Protalix BioTherapeutics

$0.403
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0061 (-1.49%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell PLX and other stocks, options, ETFs, and crypto commission-free!

About PLX

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Read More The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Employees
184
Headquarters
Carmiel, HaZafon
Founded
1993
Market Cap
60.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
549.33K
High Today
$0.418
Low Today
$0.4012
Open Price
$0.4092
Volume
345.07K
52 Week High
$0.83
52 Week Low
$0.27

Collections

Health
Therapy
Asia (Non-China)
Asia

PLX News

Yahoo FinanceJun 18

Protalix Completes Enrollment in Fabry Disease Study

176

PLX Earnings

-$0.10
-$0.07
-$0.05
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market

More PLX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.